A novel core-shell hydrogel bead was fabricated for effective removal of methylene blue dye from aqueous solutions.The core,made of sodium alginate-g-polyacrylamide and attapulgite nanofibers,was cross-linked by Calci...A novel core-shell hydrogel bead was fabricated for effective removal of methylene blue dye from aqueous solutions.The core,made of sodium alginate-g-polyacrylamide and attapulgite nanofibers,was cross-linked by Calcium ions(Ca^(2+)).The shell,composed of a chitosan/activated carbon mixture,was then coated onto the core.Fourier transform infrared spectroscopy confirmed the grafting polymerization of acrylamide onto sodium alginate.Scanning electron microscopy images showed the core-shell structure.The core exhibited a high water uptake ratio,facilitating the diffusion of methylene blue into the core.During the diffusion process,the methylene blue was first adsorbed by the shell and then further adsorbed by the core.Adsorption tests showed that the coreshell structure had a larger adsorption capacity than the core alone.The shell effectively enhanced the adsorption capacity to methylene blue compared to the single core.Methylene blue was adsorbed by activated carbon and chitosan in the shell,and the residual methylene blue diffused into the core and was further adsorbed.展开更多
BACKGROUND The objectives of this study were to assess the safety and efficacy of drug-eluting bead transarterial chemoembolization(DEB-TACE)as neoadjuvant therapy before liver transplantation(LT)for advanced-stage he...BACKGROUND The objectives of this study were to assess the safety and efficacy of drug-eluting bead transarterial chemoembolization(DEB-TACE)as neoadjuvant therapy before liver transplantation(LT)for advanced-stage hepatocellular carcinoma(HCC)and to analyze the prognostic factors.AIM To determine whether DEB-TACE before LT is superior to LT for advanced-stage HCC.METHODS A total of 99 individuals diagnosed with advanced HCC were studied retrospectively.The participants were categorized into the following two groups based on whether they had received DEB-TACE before LT:DEB-TACE group(n=45)and control group(n=54).The participants were further divided into two subgroups based on the presence or absence of segmental portal vein tumor thrombus(PVTT).The DEB-TACE group consisted of two subgroups:Group A(n=31)without PVTT and group B(n=14)with PVTT.The control group also had two subgroups:Group C(n=37)without PVTT and group D(n=17)with PVTT.Data on patient demographics,disease characteristics,therapy response,and adverse events(AEs)were collected.The overall survival(OS)and recurrence-free survival(RFS)rates were assessed using Kaplan-Meier curves.Univariate and multivariate Cox regression analyses were conducted to determine the parameters that were independently related to OS and RFS.RESULTS The DEB-TACE group exhibited an overall response rate of 86.6%.Following therapy,there was a significant decrease in the median alpha-fetoprotein(AFP)level(275.1 ng/mL vs 41.7 ng/mL,P<0.001).The main AE was post-embolization syndrome.The 2-year rates of RFS and OS were significantly higher in the DEB-TACE group than in the control group(68.9%vs 38.9%,P=0.003;86.7%vs 63.0%,P=0.008).Within the subgroups,group A had higher 2-year rates of RFS and OS compared to group C(71.0%vs 45.9%,P=0.038;83.8%vs 62.2%,P=0.047).The 2-year RFS rate of group B was markedly superior to that of group D(64.3%vs 23.5%,P=0.002).Results from multivariate analyses showed that pre-LT DEB-TACE[hazard ratio(HR)=2.73,95%confidence interval(CI):1.44-5.14,P=0.04],overall target tumor diameter≤7 cm(HR=1.98,95%CI:1.05-3.75,P=0.035),and AFP level≤400 ng/mL(HR=2.34;95%CI:1.30-4.19,P=0.009)were significant risk factors for RFS.Additionally,pre-LT DEBTACE(HR=3.15,95%CI:1.43-6.96,P=0.004)was identified as a significant risk factor for OS.CONCLUSION DEB-TACE is a safe and efficient therapy for advanced-stage HCC and also enhances patient survival after LT.展开更多
将L-脯氨酸嫁接在树脂氯球上,催化水杨醛及其衍生物和丙二酸酯直接合成香豆素-3-羧酸酯类物质,反应具有选择性强、产率高、成本低、三废少、后处理简单、催化剂可以多次重复使用等优点,符合绿色催化的特性。实验表明:反应在100℃下,醛...将L-脯氨酸嫁接在树脂氯球上,催化水杨醛及其衍生物和丙二酸酯直接合成香豆素-3-羧酸酯类物质,反应具有选择性强、产率高、成本低、三废少、后处理简单、催化剂可以多次重复使用等优点,符合绿色催化的特性。实验表明:反应在100℃下,醛和酯的摩尔比为1:1.2,催化剂的用量1 g,10 mL DMF中反应5h,反应的选择性≥98%,产率高达92%;催化剂循环使用6次反应的产率仍在85%以上。在此优化的反应条件下,高效合成了一系列其他香豆素-3-羧酸酯类物质,产品的结构和纯度通过了NMR、IR和熔点等手段进行了鉴定。展开更多
目的评估自动化磁珠法提取血清脂溶性维生素应用液相色谱串联质谱法(liquid chromatography-tandem mass spectrometry,LC-MS/MS)检测的性能。方法收集200例临床剩余血清样本,采用自动化磁珠法提取血清中脂溶性维生素A,D_(2),D_(3),E和K...目的评估自动化磁珠法提取血清脂溶性维生素应用液相色谱串联质谱法(liquid chromatography-tandem mass spectrometry,LC-MS/MS)检测的性能。方法收集200例临床剩余血清样本,采用自动化磁珠法提取血清中脂溶性维生素A,D_(2),D_(3),E和K;同时联合LC-MS/MS检测脂溶性维生素A,D_(2),D_(3),E和K的线性、定量限、精密度、正确度、携带污染率等性能指标以及基质效应。并比较此方法与传统萃取法检测结果的一致性。结果自动化磁珠法提取脂溶性维生素A,D_(2),D_(3),E和K线性相关系数均>0.99;五种物质的定量限分别为5,0.25,0.25,125和0.025ng/ml;批内精密度和批间精密度分别为0.66%~4.83%,0.15%~3.70%;平均加标回收率为87.05%~111.11%;基质效应为95.43%~99.07%;高-低值样本循环进样结果均值与低-低值样本循环进样结果均值之差,均小于低-低值样本循环进样结果均值的3s;统计学结果显示自动化磁珠法和传统萃取法提取的脂溶性维生素结果相关性良好(r>0.99),两种方法的检测结果无显著偏倚。结论自动化磁珠法提取脂溶性维生素的检测性能良好,有望提高样品通量和分析效率。展开更多
文摘A novel core-shell hydrogel bead was fabricated for effective removal of methylene blue dye from aqueous solutions.The core,made of sodium alginate-g-polyacrylamide and attapulgite nanofibers,was cross-linked by Calcium ions(Ca^(2+)).The shell,composed of a chitosan/activated carbon mixture,was then coated onto the core.Fourier transform infrared spectroscopy confirmed the grafting polymerization of acrylamide onto sodium alginate.Scanning electron microscopy images showed the core-shell structure.The core exhibited a high water uptake ratio,facilitating the diffusion of methylene blue into the core.During the diffusion process,the methylene blue was first adsorbed by the shell and then further adsorbed by the core.Adsorption tests showed that the coreshell structure had a larger adsorption capacity than the core alone.The shell effectively enhanced the adsorption capacity to methylene blue compared to the single core.Methylene blue was adsorbed by activated carbon and chitosan in the shell,and the residual methylene blue diffused into the core and was further adsorbed.
基金Supported by Project of Medical and Health Technology Program in Zhejiang Province,No.2020KY787.
文摘BACKGROUND The objectives of this study were to assess the safety and efficacy of drug-eluting bead transarterial chemoembolization(DEB-TACE)as neoadjuvant therapy before liver transplantation(LT)for advanced-stage hepatocellular carcinoma(HCC)and to analyze the prognostic factors.AIM To determine whether DEB-TACE before LT is superior to LT for advanced-stage HCC.METHODS A total of 99 individuals diagnosed with advanced HCC were studied retrospectively.The participants were categorized into the following two groups based on whether they had received DEB-TACE before LT:DEB-TACE group(n=45)and control group(n=54).The participants were further divided into two subgroups based on the presence or absence of segmental portal vein tumor thrombus(PVTT).The DEB-TACE group consisted of two subgroups:Group A(n=31)without PVTT and group B(n=14)with PVTT.The control group also had two subgroups:Group C(n=37)without PVTT and group D(n=17)with PVTT.Data on patient demographics,disease characteristics,therapy response,and adverse events(AEs)were collected.The overall survival(OS)and recurrence-free survival(RFS)rates were assessed using Kaplan-Meier curves.Univariate and multivariate Cox regression analyses were conducted to determine the parameters that were independently related to OS and RFS.RESULTS The DEB-TACE group exhibited an overall response rate of 86.6%.Following therapy,there was a significant decrease in the median alpha-fetoprotein(AFP)level(275.1 ng/mL vs 41.7 ng/mL,P<0.001).The main AE was post-embolization syndrome.The 2-year rates of RFS and OS were significantly higher in the DEB-TACE group than in the control group(68.9%vs 38.9%,P=0.003;86.7%vs 63.0%,P=0.008).Within the subgroups,group A had higher 2-year rates of RFS and OS compared to group C(71.0%vs 45.9%,P=0.038;83.8%vs 62.2%,P=0.047).The 2-year RFS rate of group B was markedly superior to that of group D(64.3%vs 23.5%,P=0.002).Results from multivariate analyses showed that pre-LT DEB-TACE[hazard ratio(HR)=2.73,95%confidence interval(CI):1.44-5.14,P=0.04],overall target tumor diameter≤7 cm(HR=1.98,95%CI:1.05-3.75,P=0.035),and AFP level≤400 ng/mL(HR=2.34;95%CI:1.30-4.19,P=0.009)were significant risk factors for RFS.Additionally,pre-LT DEBTACE(HR=3.15,95%CI:1.43-6.96,P=0.004)was identified as a significant risk factor for OS.CONCLUSION DEB-TACE is a safe and efficient therapy for advanced-stage HCC and also enhances patient survival after LT.
文摘将L-脯氨酸嫁接在树脂氯球上,催化水杨醛及其衍生物和丙二酸酯直接合成香豆素-3-羧酸酯类物质,反应具有选择性强、产率高、成本低、三废少、后处理简单、催化剂可以多次重复使用等优点,符合绿色催化的特性。实验表明:反应在100℃下,醛和酯的摩尔比为1:1.2,催化剂的用量1 g,10 mL DMF中反应5h,反应的选择性≥98%,产率高达92%;催化剂循环使用6次反应的产率仍在85%以上。在此优化的反应条件下,高效合成了一系列其他香豆素-3-羧酸酯类物质,产品的结构和纯度通过了NMR、IR和熔点等手段进行了鉴定。
文摘目的评估自动化磁珠法提取血清脂溶性维生素应用液相色谱串联质谱法(liquid chromatography-tandem mass spectrometry,LC-MS/MS)检测的性能。方法收集200例临床剩余血清样本,采用自动化磁珠法提取血清中脂溶性维生素A,D_(2),D_(3),E和K;同时联合LC-MS/MS检测脂溶性维生素A,D_(2),D_(3),E和K的线性、定量限、精密度、正确度、携带污染率等性能指标以及基质效应。并比较此方法与传统萃取法检测结果的一致性。结果自动化磁珠法提取脂溶性维生素A,D_(2),D_(3),E和K线性相关系数均>0.99;五种物质的定量限分别为5,0.25,0.25,125和0.025ng/ml;批内精密度和批间精密度分别为0.66%~4.83%,0.15%~3.70%;平均加标回收率为87.05%~111.11%;基质效应为95.43%~99.07%;高-低值样本循环进样结果均值与低-低值样本循环进样结果均值之差,均小于低-低值样本循环进样结果均值的3s;统计学结果显示自动化磁珠法和传统萃取法提取的脂溶性维生素结果相关性良好(r>0.99),两种方法的检测结果无显著偏倚。结论自动化磁珠法提取脂溶性维生素的检测性能良好,有望提高样品通量和分析效率。
